¤p¨à¥ÎÃĦw¥þ
¦ó¿×¤p¨à
- ¦²£¨à¡GÃh¥¥¶g¼Æ¤p©ó38¶g„Æ
- ¨¬¤ë·s¥Í¨à¡G º¡¤ë«e„Æ
- À¦¨à¡G¶g·³«e„Æ
- ¥®¨à¡G1-5·³„Æ
- ¨àµ£¡G6-12·³„Æ
- ¤Ö¦~¡G13-18·³
¤p¨à¾¯¶qªº¦~ÄÖpºâ
- ªì¥Í-1Ӥ릨¤H¥ÎÃĶqªº1/18-1/14
- 1-6Ӥ릨¤H¥ÎÃĶqªº1/14-1/7
- 6Ó¤ë-1·³¦¨¤H¥ÎÃĶqªº1/7-1/5
- 1-2·³¦¨¤H¥ÎÃĶqªº1/5-1/4
- 2-4·³¦¨¤H¥ÎÃĶqªº1/4-1/3
- 4-6·³¦¨¤H¥ÎÃĶqªº1/3-2/5
- 6-9·³¦¨¤H¥ÎÃĶqªº2/5-1/2
- 9-12·³¦¨¤H¥ÎÃĶqªº1/2-2/3
Young¡¦s Rule ·¨¤ó¤½¦¡¡]¾A¥Î©ó2-12·³¨àµ£¡^
¨àµ£¾¯¶q = ¦¨¤H¾¯¶q ¡Ñ¡]¨àµ£¦~ÄÖ / ¨àµ£¦~ÄÖ + 12¡^
Fried Rule¡]¾A¥Î©ó2·³¥H¤U¨àµ£¡^
¨àµ£¾¯¶q = ¦¨¤H¾¯¶q ¡Ñ¡]¥Í«á¤ë¼Æ / 150¡^
Cowling¡¦s Rule ¬ì¤ó¤½¦¡
¨àµ£¾¯¶q = ¦¨¤H¾¯¶q ¡Ñ¡]¨àµ£¦~ÄÖ + 1 / 24¡^
¤p¨à¾¯¶qªºÅ髤ÎÅéªí±¿npºâªk
- A.Clark¡¦s Rule
¨àµ£¾¯¶q = ¦¨¤H¾¯¶q ¡Ñ¡]¨àµ£½S« / 150¡^©Î¡i¡]kg ¡Ñ 2.2¡^/150¡j
- B.¨àµ£¾¯¶q = ¦¨¤H¾¯¶q ¡Ñ¡]m2 / 1.73m2¡^
*¤@¯ëÃĨå°O¸ü¤§¾¯¶q¦~ÄÖ¬°20¡ã60·³¡C
*13·³¥H¤W¯àªA¥Î¦¨¤H¾¯¶q¡C
¤p¨à¸Ñ¼öÂíµh¾¯
FDA®Ö㤧¤p¨à°h¿NÃĪ«¡G
aspirin,acetaminophen ¤Î ibuprofen
aspirin¦]¥i¯à¤Þ°_¤p¨à¹p¤ó¯gÔ¸s(Reye¡¥s syndrome)¡A¨Ã¤£«Øij¨Ï¥Î
µo¿N¥»¨¬O¤@ºØ¯gª¬(symptom)¦Ó«D¯e¯f(disease)¦b37.8oC~o40C¤§¶¡¤@¯ë¤£·|¹ï¤p«Ä¦³¶Ë®`
°h¿N¥u¬On´î»´¤£µÎªA¯gª¬¡A¨Ã¤£·|ÁYµu¯fµ{
acetaminophen ¤Î ibuprofen¨âªÌ°h¿N®ÄªG¬Û·í¡A¦ýibuprofen¹ï>39oC®É°·Å®ÄªGÀu©óacetaminophen acetaminophen¡A1~1.5¤p®É¹F³Ì¤j°·Å®ÄªG¡F
¨x¬r©Ê¸û¤j¤H¬°§C¡A¦]¡G
¥NÁÂ¥Dn¸g¥Ñ¨xŦsulfate conjugation(¤j¤H¬°glucuronide conjugation)²£¥Í¤¤¶¡¥NÁª«N-acetyl-p-benzoquinonimine(NAPQI)¸û¤Ö
¤p«Ä¨xŦ¤§glutathion¸û¦h
ibuprofen©ó1~2¤p®É¹F³Ì°ª¦å¤¤¿@«×¡A¥Dn¸g¥Ñ¨xŦ®ñ¤Æ¥NÁÂ
¤p¨à¸T§ÒÃÄ«~
ÃÄ«~:aspirin
¤£¨}¼vÅT:¹p¤ó¯g
¸T§Ò±Ú¸s:¤p¨à¤ôµk©Î¬y¦æ©Ê·P«_
¥®¨àªAÃı`¨£°ÝÃD
ÃĦR¥X¨Ó¸Ó«ç»ò¿ì¡H
¦p¤p«Ä¦YÃÄ«á¦R¥X¨Ó¡A»Ýµû¦ô¦R¥Xªº¶q¦³¦h¤Ö¡A¤~¨M©w¦p¦ó¸É±Ï¡C¦pªG¤pªB¤Í¦YÃĤ§«á¦R¥X¨Óªº¶q¤£¦h¡A´N¤£¥²¸É¦Y¡A¤@¤p®É¤º¦³¦RÃĪº±¡§Î¡A¥i¦A¸É¥R¥b¶q¡AY¦b¤G¤p®É¤§«á¤~¦R¡A«h¥i¤£¥²¸É¥R¤]¤£¥²´£¦¤U¤@¦¸¦YÃĪº®É¶¡¡C¦pªG½T©w¥þ³¡³£¦R¥X¨Ó¡A«hÀ³¦A¹j10¨ì15¤ÀÄÁ«á¤~¸É¦Y¡A¥H§K«Ä¤l§Ü©Ú¡C ¦ý¦p¤j³¡¤À³£¦R¥X¨Ó¡A¥BµLªk§PÂ_¦Y¶i¥h¦h¤Ö¡A«hÀ³Æ[¹î¥b¤p®É¡AYÁÙ«ùÄòµo¿N¤£°h¤~¦Ò¼{¸É¦Y¡CY¦YÃÄ«á¥X²{¤£¥¿±`¹Ã¦R¡A¥B¦³©âÝz±¡§ÎÀ³ºò«æ°eÂå¡C ¦pªG¤p«Ä¿©±wªº¬O¸zG«¬¯e¯f¡A¤@¦Y´N¦R¡A¦³®É¸T¹§Y¥i²¬Â¡¡A¦pÄY«¦Ü¸zG¤wµLªk§l¦¬¥ô¦óªF¦è¡]¥]¬AÃĪ«¡^¡A«hÀ³¦Ò¼{¥H¥´°w©M¥´ÂIºwªvÀø
À¦¨àªAÃÄ ³Ì¦n¦bÀ\«e
µL½×¤°»ò¦~ÄÖªº¯f¨àÁýÃĮɳ£¤£¥i¥½ö¡A¥¼º¡©P·³¥H«eªºÀ¦¨àÀ³©ê¦bÃh¸Ì±Ä¥b§¤«º¡A¥B¥õ¨¤°ª©ó45«×¡CªAÃĮɶ¡³Ì¦n¬O¦bÀ\«e¥b¤p®É¦Ü¤@¤p®É¡AªAÃÄ«e¤£nÁý¥¤©MÁý¤ô¡AÀ¦¨à²¤¦³°§¾j·P¤ñ¸û·|¥D°Ê±NÃħ]¤U¥h
¨ä¥Lª`·N¨Æ¶µ
¹ï©óµo¿Nªº¯fµ£¡AÂå¥Í·|µ¹¤©°h¿NÃĤô¡A¥H³Æµo¿N38.5¢J¡]¨z·Å¡^®É¨Ï¥Î¡C°h¿N¾¯¤@¯ë¦b30¤ÀÄÁ«á·|¶}©l§@¥Î¡A¤@¤p®É«á¥i³vº¥¨ì¹F³Ì¤jÃĮġAY¿N¨S°h«h¥i©ó4¤p®É«á¦A«½Æµ¹¤©°h¿NÃľ¯¡CY§ëÃÄ1¤p®É¹L«á¤´«ùÄòµo¿N¦Ü39¢J¡A¦¹®É¥iµ¹¤©°h¿N®ê¾¯¡C¦ýYÃÄ¥]§t¦³°h¿NÃį»¡A»Ý©ó30¤ÀÄÁ«á¤~¥i¨Ï¥Î°h¿NÃĤô©Î®ê¾¯